Related Experiment Video
Updated: May 2, 2026
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
Panitumumab : leading to better overall survival in metastatic colorectal cancer?
Ana Sebio1, Sebastian Stintzing, Stefan Stremitzer
1University of Southern California, Keck School of Medicine, Norris Comprehensive Cancer Center, Division of Medical Oncology , 1441 Eastlake Avenue, Los Angeles, CA 90033 , USA +1 323 865 3967 ; +1 323 865 0061 ; LENZ@usc.edu.
Introduction:
Survival of metastatic colorectal cancer (mCRC) patients has improved greatly over the past few years, essentially due to the appearance of new biological therapies. Among these new therapies, monoclonal antibodies targeting the EGFR are the leading contributors to the so-called personalized medicine. Biomarkers within the EGFR pathway, such as K-Ras mutation, have proved to help better select the patients benefiting from these treatments.
Areas Covered:
Panitumumab is a fully human monoclonal antibody that targets the EGFR and is currently approved in combination with chemotherapy or in monotherapy for the treatment of mCRC patients. Following a description of the pharmacological and tolerability data, this review focuses on the clinical activity of panitumumab through the description of clinical trials and biomarker research.
Expert Opinion:
Recent biomarker research with expanded Ras testing has led to an improvement in overall survival for all Ras wild-type patients treated with panitumumab. Furthermore, the thorough evaluation of markers within the EGFR pathway could potentially prevent detrimental effects for patients treated with panitumumab and avoid unnecessary toxicity and costs.
Insights
Panitumumab, an epidermal growth factor receptor (EGFR) antibody, improves survival in metastatic colorectal cancer (mCRC) patients. Expanded Ras testing enhances patient selection for this targeted therapy, optimizing outcomes.
Area of Science:
- Oncology
- Pharmacology
- Genetics
Background:
- Metastatic colorectal cancer (mCRC) survival has significantly improved due to novel biological therapies.
- Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) are key to personalized medicine in mCRC.
- Biomarkers like K-Ras mutations aid in selecting patients who benefit most from EGFR-targeted treatments.
Purpose of the Study:
- To review the clinical activity and biomarker research of panitumumab, an EGFR-targeting monoclonal antibody.
- To discuss the pharmacological and tolerability data of panitumumab in mCRC treatment.
- To highlight the impact of biomarker research on panitumumab efficacy.
Main Methods:
- Review of clinical trials investigating panitumumab in mCRC.
- Analysis of biomarker research, including expanded Ras testing.
- Evaluation of pharmacological and tolerability data for panitumumab.
Main Results:
- Panitumumab demonstrates clinical activity in mCRC patients.
- Expanded Ras testing has improved overall survival for Ras wild-type patients treated with panitumumab.
- Biomarker research is crucial for patient stratification and treatment optimization.
Conclusions:
- Recent biomarker research, particularly expanded Ras testing, has improved overall survival in Ras wild-type mCRC patients receiving panitumumab.
- Comprehensive evaluation of EGFR pathway markers can prevent adverse effects and reduce unnecessary toxicity and costs.
- Personalized medicine approaches using biomarkers are vital for optimizing panitumumab therapy in mCRC.
More Related Videos
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016